Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma
Conditions: Lung Cancer; Carcinoma, Squamous Cell Interventions: Drug: Osimertinib Sponsors: The First Affiliated Hospital of Guangzhou Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hospitals | Lung Cancer | Neoadjuvant Therapy | Research | Skin Cancer | Squamous Cell Carcinoma